European equities traded in the US as American depositary receipts were slightly higher late Thursday morning, edging 0.10% higher to 1,298.82 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by furniture maker Natuzzi (NTZ) and medical device maker EDAP TMS (EDAP), which climbed 18% and 7.3% respectively. They were followed by telecommunications company VEON (VEON) and biopharmaceutical company Genfit (GNFT), which were up 2.5% each.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which dropped 2.8% and 2.6% respectively. They were followed by accommodations booking company trivago (TRVG) and 3D printer company Materialise (MTLS), which were off 0.7% each.
From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Verona Pharma (VRNA), which increased 2.2% and 2% respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and TC Biopharm (TCBP), which rose 1.8% and 1% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and biotech firm Trinity Biotech (TRIB), which dropped 3.8% and 3% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and pharmaceutical company Silence Therapeutics (SLN), which lost 1.6% and 1.5% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。